Ramana Chennubhotla, MD
Endocrinology, Diabetes & Metabolism · Elizabethtown, KYNPI 1366498339
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,215 and has fallen 94.1% since, to $131 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in KY, where the typical reported total is $3,450.
Across 174 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$399
- Medtronic$317
- Abbott$300
- Amneal Pharmaceuticals LLC$244
- Amarin Pharma, Inc.$227
- Sanofi-aventis U.S. LLC$201
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,75894%
- Education$1876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $399 |
| Medtronic(2 entities) | 10 | $317 |
| Abbott | 8 | $300 |
| Amneal Pharmaceuticals LLC | 12 | $244 |
| Amarin Pharma, Inc. | 17 | $227 |
| Sanofi-aventis U.S. LLC | 12 | $201 |
| Boehringer Ingelheim | 17 | $186 |
| Radius Health, Inc. | 4 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $131 |
| Mannkind Corporation | 7 | $97 |
| Lilly USA, LLC | 6 | $94 |
| AbbVie | 5 | $83 |
| Amgen | 5 | $72 |
| AstraZeneca | 5 | $66 |
| Shire North American Group Inc | 4 | $60 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Merck | 3 | $43 |
| Johnson & Johnson | 3 | $42 |
| Antares Pharma, Inc. | 2 | $37 |
| Corcept Therapeutics | 2 | $35 |
| Dexcom, Inc. | 2 | $34 |
| Insulet Corporation | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Lite system$140
- CRENESSITY$131
- Minimed 670G System$109
- Tymlos$105
How this compares
$2,944 in reported general payments places this provider in the 40th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $181,690 |
| MounjaroTirzepatide | 125 | $148,376 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $70,639 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 68 | $62,319 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $58,309 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $46,226 |
| TrulicityDulaglutide | 20 | $41,651 |
| JardianceEmpagliflozin | 33 | $38,846 |
| FarxigaDapagliflozin Propanediol | 42 | $35,829 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $33,387 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $28,051 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $22,025 |
| Cinacalcet Hcl | 150 | $19,526 |
| Novolog FlexpenInsulin Aspart | 73 | $18,495 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 41 | $17,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $94 | $196,216160 claims |
| Novo NordiskOzempic | $399 | $181,690144 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog | $201 | $64,24579 claims |
| Boehringer IngelheimJardiance, Glyxambi | $186 | $44,66247 claims |
| AstraZenecaFarxiga | $66 | $35,82942 claims |
| MerckJanuvia | $43 | $14,13319 claims |
| AbbVieSynthroid | $83 | $11,895163 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $244 | $3,146265 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Elizabethtown
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Moussa AlhajAshland$111K
- Mehdi PoorkayLouisville$81K
- Lyle MyersLexington$60K
- Wendell MiersLexington$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.